Bilastine: Clinical Overview
Bilastine is a highly selective, non-sedating second-generation H1-antihistamine indicated for allergic rhinoconjunctivitis and chronic spontaneous urticaria, with a favorable safety profile characterized by minimal CNS penetration, no drug-drug interactions via CYP450, and no dose adjustments needed for renal or hepatic impairment.
Indications
Bilastine is approved for:
- Allergic rhinoconjunctivitis (seasonal and perennial)
- Chronic spontaneous urticaria (CSU)
- Urticaria (acute and chronic)
Dosing Regimen
Standard Dosing
- Adults and adolescents ≥12 years: 20 mg once daily 1, 3
- Children 6 to <12 years: 10 mg once daily 1
- Children 4-11 years weighing ≥16 kg: 10 mg once daily 1
- Children 2-5 years: 10 mg once daily (orodispersible tablets) 4
Up-Dosing for Refractory CSU
Bilastine has Grade A recommendation for up-dosing in chronic spontaneous urticaria 1. The stepwise approach is:
- Start with standard dose (20 mg once daily)
- If inadequate response after 2-4 weeks, increase up to 4 times the standard dose (80 mg daily)
- Administer as 2 tablets twice daily for convenience 1
- If symptoms persist >4 weeks despite fourfold dosing, add omalizumab 1
Bilastine 40 mg daily has demonstrated efficacy in refractory CSU with significant cytokine modulation (IL-6 and IL-17 reduction) 5
Pharmacological Profile
Key Advantages
- Non-sedating: H1-receptor occupancy ≤20% (classified as non-sedative group alongside fexofenadine) 1
- Rapid onset: Peak plasma concentrations within 1 hour; clinical effects within 1-4 hours 1, 4
- Long duration: 24-hour action allowing once-daily dosing 1
- No CYP450 interactions: Undergoes negligible metabolism, almost exclusively renal excretion 6, 3, 7
- No P-glycoprotein substrate effects on CNS penetration 7
Contraindications
No specific contraindications listed in current guidelines 1. However, standard precautions apply for hypersensitivity to bilastine or excipients.
Adverse Effects
Common Side Effects
Bilastine is exceptionally well-tolerated with minimal adverse effects:
- Headache (most common)
- Somnolence: 0.4-3% (comparable to placebo) 8
- No anticholinergic effects 3
- No cardiotoxicity (no QT prolongation) 7, 9
- No impairment of driving ability 7, 9
In pediatric studies (ages 2-5 years), only 21.6% experienced any treatment-emergent adverse event, none severe 4
High-Dose Safety
At doses up to 80 mg daily (4× standard), bilastine maintains favorable safety profile with no significant increase in adverse events compared to standard dosing 5
Drug Interactions
Bilastine has virtually no clinically significant drug interactions 6, 3. Specifically:
- No interactions with: Anticoagulants (including NOACs), antiretrovirals, antituberculosis drugs, corticosteroids, digoxin, oral contraceptives, proton pump inhibitors 6
- Does not induce or inhibit CYP450 isoenzymes 6, 7
- No dosage adjustment needed with concomitant medications 2
Food Interaction
Take on empty stomach: Food may reduce absorption, though this is not emphasized as a major clinical concern in guidelines 3
Special Populations
Renal Impairment
No dose adjustment required 3, 7
Hepatic Impairment
No dose adjustment required 3, 7
Elderly
No dose adjustment required; suitable for elderly patients even with compromised organ function 2, 3
Pregnancy and Lactation
Limited data available. Loratadine, cetirizine, desloratadine, and fexofenadine are preferred during pregnancy based on more extensive safety data 1. Bilastine is not specifically mentioned in pregnancy guidelines for CSU.
Pediatrics
- Approved down to age 2 years with 10 mg daily dosing 4
- Pharmacokinetics linear and consistent across pediatric age groups (2-12 years) 4
- Body weight and age are not significant covariates requiring dose adjustment 4
Clinical Efficacy
Chronic Spontaneous Urticaria
- Response rates with up-dosing: 43% well-controlled (UAS7 <6), 10% complete response (UAS7 = 0) at 12 weeks 5
- Symptom control in ~50% with standard dose; ~63% with up-dosing 1
- Cytokine modulation: Significant reduction in IL-6 and IL-17 levels 5
Allergic Rhinoconjunctivitis
- Efficacy comparable to cetirizine and desloratadine 9
- Improves all nasal and ocular symptoms 9
- Enhances quality of life 3, 9
Treatment Duration and Discontinuation
- Continue until disease remission (minimum 3-6 months of complete control, UCT = 16) 1
- Standard dose: Stop abruptly or every other day for 1-2 weeks 1
- High dose: Reduce by 1 tablet monthly or halve dose weekly 1
- Relapse is common on withdrawal; restart last effective dose 1
Monitoring
No laboratory monitoring required 1. Track symptom control using:
- Urticaria Activity Score 7 (UAS7)
- Urticaria Control Test (UCT)
- CRUSE app for simultaneous monitoring 1
Clinical Pearls
- Bilastine is classified as non-sedating with fexofenadine, making it ideal for patients requiring alertness 1
- Grade A recommendation for up-dosing distinguishes it from some other antihistamines 1
- Absence of drug interactions makes it particularly suitable for elderly and polypharmacy patients 2, 6
- Regular daily dosing is superior to on-demand use 1
- Do not combine different antihistamines; up-dose monotherapy is preferred 1